1. Home
  2. UNCY vs SNCR Comparison

UNCY vs SNCR Comparison

Compare UNCY & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UNCY
  • SNCR
  • Stock Information
  • Founded
  • UNCY 2016
  • SNCR 2000
  • Country
  • UNCY United States
  • SNCR United States
  • Employees
  • UNCY N/A
  • SNCR N/A
  • Industry
  • UNCY Biotechnology: Pharmaceutical Preparations
  • SNCR EDP Services
  • Sector
  • UNCY Health Care
  • SNCR Technology
  • Exchange
  • UNCY Nasdaq
  • SNCR Nasdaq
  • Market Cap
  • UNCY 74.2M
  • SNCR 71.4M
  • IPO Year
  • UNCY 2021
  • SNCR 2006
  • Fundamental
  • Price
  • UNCY $4.63
  • SNCR $5.58
  • Analyst Decision
  • UNCY Strong Buy
  • SNCR Strong Buy
  • Analyst Count
  • UNCY 5
  • SNCR 1
  • Target Price
  • UNCY $55.20
  • SNCR $13.00
  • AVG Volume (30 Days)
  • UNCY 510.5K
  • SNCR 53.0K
  • Earning Date
  • UNCY 11-12-2025
  • SNCR 11-11-2025
  • Dividend Yield
  • UNCY N/A
  • SNCR N/A
  • EPS Growth
  • UNCY N/A
  • SNCR N/A
  • EPS
  • UNCY N/A
  • SNCR N/A
  • Revenue
  • UNCY N/A
  • SNCR $171,870,000.00
  • Revenue This Year
  • UNCY N/A
  • SNCR $1.36
  • Revenue Next Year
  • UNCY $4,481.14
  • SNCR $5.22
  • P/E Ratio
  • UNCY N/A
  • SNCR N/A
  • Revenue Growth
  • UNCY N/A
  • SNCR 2.54
  • 52 Week Low
  • UNCY $3.40
  • SNCR $5.25
  • 52 Week High
  • UNCY $11.00
  • SNCR $13.96
  • Technical
  • Relative Strength Index (RSI)
  • UNCY 61.71
  • SNCR 36.77
  • Support Level
  • UNCY $3.72
  • SNCR $5.60
  • Resistance Level
  • UNCY $4.80
  • SNCR $6.00
  • Average True Range (ATR)
  • UNCY 0.24
  • SNCR 0.34
  • MACD
  • UNCY 0.07
  • SNCR -0.05
  • Stochastic Oscillator
  • UNCY 75.00
  • SNCR 4.07

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

Share on Social Networks: